Search Results
488 results found for "Cost-efficient medications https://simplemedrx.top"
- Anavex to Present at Third Annual MHPAEA Business Roundtable in Washington, D.C.
About Alzheimer’s Disease Today, Alzheimer’s disease remains the largest unmet medical need in neurology More than 25 million people are currently diagnosed with Alzheimer’s, with the associated cost of care (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Expands Management Team
impressive pipeline consisting of potential breakthrough therapies for indications with very high unmet medical (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Independent Research Describes ANAVEX 3-71 as Potent Cognitive Enhancer in Alzheimer's Disease Model
The results of the preclinical study demonstrate that ANAVEX 3-71: Protects post-synaptic dendritic spines Results show that ANAVEX 3-71 efficiently rescues mushroom spines via potential activation of sigma-1 Israel Institute for Biological Research (Ness-Ziona, Israel), the University of Texas Southwestern Medical projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Announces Executive Overseeing Regulatory Affairs
clinical trial staffing and oversight for more than 60 clinical trials at both Columbia University Medical Capiak participated in translational medical research at the University of Michigan Medical School through (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Announces Preparation of Regulatory Filings based on Guidance From the FDA
innovative trial design for ANAVEX 2-73 in Alzheimer’s treatment, it is believed that this is more efficient About Alzheimer’s Disease Today, Alzheimer’s disease remains the largest unmet medical need in neurology More than 25 million people are currently diagnosed with Alzheimer’s, with the associated cost of care projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Confirms Data for Phase 2a Alzheimer's Trial for ANAVEX 2-73
We remain dedicated to advancing ANAVEX 2-73 through the ongoing Phase 2a trial and to reporting new (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Announces Positive Primary and Secondary Endpoints were Achieved in a Phase 2a Clinical Trial
About Alzheimer’s Disease Today, Alzheimer’s disease remains the largest unmet medical need in neurology More than 25 million people are currently diagnosed with Alzheimer’s, with the associated cost of care Clinical Trials for Alzheimer’s Disease (CTAD) gather more than 800 global researchers to review the most (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Announces CTAD 2015 Abstract
(NASDAQ: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Commences Trading on NASDAQ Today — To Ring Friday's Closing Bell
ET via live webcast at https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Announces Uplisting to NASDAQ
(AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug candidates projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex to Present at 4th Annual OktoberINVESTfest Conference
(OTCQX:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex to Present Interim Phase 2a Clinical Trial Data of ANAVEX 2-73 at Late-Breaking Oral Session
(OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
